(Q36733271)

16 August 2017

1 reference

title

Narcolepsy with cataplexy (English)

1 reference

16 August 2017

0 references

Isabelle Arnulf

2

0 references

Emmanuel Mignot

series ordinal

3

object named as

Emmanuel Mignot

1 reference

16 August 2017

1

Yves Dauvilliers

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

369

1 reference

16 August 2017

issue

9560

1 reference

16 August 2017

page(s)

499-511

1 reference

Clinical aspects and pathophysiology of narcolepsy

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

The neurobiology, diagnosis, and treatment of narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Prevalence of narcolepsy symptomatology and diagnosis in the European general population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

The prevalence of narcolepsy among Chinese in Hong Kong.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Reduced number of hypocretin neurons in human narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Concomitant loss of dynorphin, NARP, and orexin in narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Age at onset of narcolepsy in two large populations of patients in France and Quebec.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Factors associated with a delay in the diagnosis of narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

A comparison of sleep deprivation and narcolepsy in terms of complex cognitive performance and subjective sleepiness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Corticospinal excitability during laughter: implications for cataplexy and the comparison with REM sleep atonia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Unusually prolonged rebound cataplexy after withdrawal of fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Prevalence of hallucinations and their pathological associations in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

A putative link between childhood narcolepsy and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Effects of bromocriptine on periodic limb movements in human narcolepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

The association between narcolepsy and REM behavior disorder (RBD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Sleep disorders and depressive feelings: a global survey with the Beck depression scale

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Effect of age on MSLT results in patients with narcolepsy-cataplexy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Narcolepsy-cataplexy. II. Psychosocial consequences and associated psychopathology.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Vigilance and automobile accidents in patients with sleep apnea or narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Differential diagnosis in hypersomnia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

The occurrence of sleep-disordered breathing among middle-aged adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Narcolepsy: selective hypocretin (orexin) neuronal loss and multiple signaling deficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Idiopathic Hypersomnia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Kleine-Levin syndrome: a systematic review of 186 cases in the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Differences in nocturnal and daytime sleep between primary and psychiatric hypersomnia: diagnostic and treatment implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Parkinson's disease and sleepiness: an integral part of PD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin heavy-chain switch-like segment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Hypocretin levels in sporadic and familial cases of canine narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

The hypocretins and sleep

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Neurons containing hypocretin (orexin) project to multiple neuronal systems

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Hypocretin (orexin) deficiency in human narcolepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Analysis of hypocretin (orexin) antibodies in patients with narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

CSF hypocretin levels in Guillain–Barré syndrome and other inflammatory neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Hypocretins (orexins) and sleep-wake disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

The genetics of narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

DQB1-0602 (DQw1) is not present in most nonDR2 Caucasian narcoleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

The genetics of sleep disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Genes for normal sleep and sleep disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Significant association of a single nucleotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

TNFA promoter polymorphisms and narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Polymorphisms of the tumor necrosis factor receptors: no association with narcolepsy in German patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with human narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

ApoE polymorphisms in narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

MAO-A and COMT polymorphisms and gene effects in narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Analysis of the monoamine oxidase genes and the Norrie disease gene locus in narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Screening for candidate gene regions in narcolepsy using a microsatellite based approach and pooled DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Genetic and familial aspects of narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Family studies in narcolepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Linkage of human narcolepsy with HLA association to chromosome 4p13-q21

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

A narcolepsy susceptibility locus maps to a 5 Mb region of chromosome 21q.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Month of birth as a risk factor for narcolepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

The month-of-birth pattern in narcolepsy is moderated by cataplexy severity and may be independent of HLA-DQB1*0602.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Pharmacotherapy for cataplexy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Sodium oxybate improves excessive daytime sleepiness in narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Modafinil binds to the dopamine uptake carrier site with low affinity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Mazindol in long-term treatment of narcolepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Clomipramine and clonazepam in cataplexy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Fluoxetine in the treatment of cataplexy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Emerging drugs for narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Emerging therapies in narcolepsy-cataplexy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Therapeutic effects of mazindol on narcolepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

The gamma-hydroxybutyrate signalling system in brain: organization and functional implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960237-2

7 January 2021

10.1016/S0140-6736(07)60237-2

Identifiers

DOI

1 reference

16 August 2017

1 reference